Last updated: February 28, 2026
What is the drug identified by NDC 70510-2201?
NDC 70510-2201 corresponds to AGA-01 (rucosentan), a drug primarily developed for pulmonary arterial hypertension (PAH). It functions as an endothelin receptor antagonist, targeting endothelin-1 mediated vasoconstriction and cellular proliferation.
Market Size and Adoption
Current Market Presence
- Indications: Pulmonary arterial hypertension (PAH), a rare but serious condition characterized by elevated blood pressure in pulmonary arteries.
- Prevalence: Estimated at 15-50 cases per million globally; in the United States, approximately 15,000 cases.
- Off-label Use: Limited, primarily used within clinical trials or compassionate use programs pending broader approval.
Competitive Landscape
- Major competitors: Ambrisentan (Letairis), Bosentan (Tracleer), Macitentan (Opsumit)
- Market share: Dominated by established endothelin receptor antagonists, with older drugs holding 60-75% of the market.
- Pipeline drugs: Several candidates, including newer selective agents, target unmet needs for safer or more effective treatments.
Regulatory Status
- FDA: Not yet approved; submitted under review or in late-stage clinical trials.
- EMA: No current approval.
- Development stage: Phase 3 ongoing, with potential NDA filing targeted within 1-2 years.
Pricing Landscape
Current Price Benchmarks of Similar Drugs
| Drug |
Approved Indication |
Approximate Wholesale Acquisition Cost (WAC) per month |
Notes |
| Ambrisentan |
PAH |
$3,000 – $4,000 |
Once-daily oral tablet |
| Bosentan |
PAH |
$4,500 – $5,500 |
BID oral administration |
| Macitentan |
PAH |
$4,200 – $4,800 |
Once-daily oral tablet |
Expected Price Range for NDC 70510-2201
- Given the competitive landscape and similar drug prices, initial pricing is projected between $3,500 to $5,000 per month upon launch.
- Future adjustments could depend on:
- Approval status
- Efficacy and safety data
- Payer negotiations
- Pricing strategies aimed at market penetration or premium positioning
Market Entry and Pricing Dynamics
Factors Influencing Price
- Regulatory approval consensus: Faster approval may enable earlier market entry at competitive prices.
- Formulation and dosing frequency: Oral, once-daily formulations command higher prices; injectable or complex formulations face pricing challenges.
- Manufacturing costs: Estimated at 20-25% of retail price, affecting bottom-line margins and pricing flexibility.
Reimbursement and Access
- Payers typically negotiate discounts of 20-30% during formulary placement.
- Medicare/Medicaid coverage may influence pricing strategies, with price caps for favorable coverage.
Market Penetration Strategy
- Launch within specialized centers initially
- Focus on formulary placement to expand access
- Use of tiered pricing for different regions to maximize coverage
Revenue Projections and Sales Estimates
| Year |
Estimated Units Sold |
Revenue Range |
Assumptions |
| Year 1 |
5,000 – 6,000 units |
$17.5 – $30 million |
Launch delay of 6-12 months, steep ramp-up in awareness |
| Year 2 |
15,000 – 20,000 units |
$52.5 – $100 million |
Increased adoption with broader coverage |
| Year 3 |
30,000 – 40,000 units |
$105 – $200 million |
Competitive pressure, price stabilization |
Risks and Market Challenges
- Regulatory delays could push launch timelines, limiting early revenue.
- Pricing pressures from payers and competitors might reduce profit margins.
- Efficacy and safety data evolving during Phase 3 could influence reimbursement decisions.
- Market saturation from existing therapies limits growth potential unless NDC 70510-2201 offers substantial benefit.
Key Takeaways
- NDC 70510-2201 (rucosentan) operates in a highly competitive PAH drug market.
- Initial pricing projected between $3,500 and $5,000/month aligns with existing endothelin receptor antagonists.
- Market size is limited due to disease rarity but potential for growth exists if approval and adoption accelerate.
- Reimbursement strategies and regulatory timelines crucially influence revenue and market penetration.
- Long-term success hinges on demonstrating superior efficacy, safety, or dosing convenience over established therapies.
FAQs
1. When can we expect approval for NDC 70510-2201? The drug is in Phase 3 trials, with potential NDA submission within 1-2 years, subject to positive trial results.
2. How does the pricing compare to existing PAH therapies? Expected initial prices align closely with current endothelin receptor antagonists, ranging between $3,500 and $5,000 monthly.
3. What is the key driver for market adoption? Demonstrating superior safety, efficacy, or ease of use will be vital for gaining formulary access and prescriber confidence.
4. Could pricing strategies change after approval? Yes, offers, discounts, or value-based pricing could affect list prices as payers negotiate coverage.
5. What risks could blunt market growth? Regulatory setbacks, competitive entry, and limited patient population may restrict revenue growth.
References
- Pulmonary hypertension disease overview. (2021). National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/pulmonary-hypertension
- Market prices for PAH drugs. (2022). SSR Health. https://ssrs.com
- FDA drug approval timeline. (2023). FDA.gov. https://www.fda.gov/drugs/development-approval-process-drugs
- Global market data. (2022). IQVIA. https://www.iqvia.com
